Adjuvant therapy no significant increase disease free survival
- This topic has 3 replies, 2 voices, and was last updated 7 years, 8 months ago by
.
-
Posts
-
Billy….Dr. Juan Valle presented on this trial at the 2017 Annual Conference
http://cholangiocarcinoma.org/misc/2017-cholangiocarcinoma-foundation-annual-conference/conference-in-review/nggallery/page/2Day 1, 4th presentation
Hugs
MarionVtkb……..thanks for looking at it more closely. It really is all about the intricacies of the data. Let’s see if I can find out more details.
Hugs
Marionhttp://meetinglibrary.asco.org/content/176861-195 :thats a link to see the abstract of results. Although not statistically significant, there was a trend for better median RFS (30 months vs 22 months) in the GEMOX group. I wonder if they looked deeper to see if there was a significant difference among those who were R1 or lymph node positive.
-BillyThis randomized phase III trial is studying giving gemcitabine hydrochloride together with oxaliplatin to see how well it works compared with observation in treating patients with biliary tract cancer that has been removed by surgery.
PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial
https://clinicaltrials.gov/ct2/show/NCT01313377Conclusions: Adjuvant chemotherapy in BTC with GEMOX was feasible and associated with expected toxicities and no deterioration of HrQoL. There was no significant difference in RFS between GEMOX and surveillance.
RFS (relapse free survival) or DFS (disease free survival) measures the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
- The forum ‘Clinical Trials’ is closed to new topics and replies.